Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Finlabo SIM Spa
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sanofi SA Wins Japanese Government's Approval for Lyxumia Drug-Reuters


Friday, 28 Jun 2013 02:09am EDT 

Reuters reported that Sanofi SA said it won approval from the Japanese government for its Lyxumia drug for the treatment of Type 2 diabetes in combination with basal insulin. Lyxumia is part of a new class of diabetes treatments called GLP-1 analogues which prompt the body to release insulin when a diabetic's blood sugar level climbs too high. Lyxumia has already been approved in Mexico, the European Union and Australia. 

Company Quote

84.9
1.47 +1.76%
11:38am EDT